BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Drug Development

  Neurana Pharma Reports Successful Results in Study Designed to Confirm the Non-Sedative Effects of Tolperisone, a Novel Skeletal Muscle Relaxant

  Neurana Pharma today announced the successful top-line results from a clinical trial designed to confirm the non-sedative effects of tolperisone.

  October 26, 2017

   · 

  4 min read
• Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market

  Hutchison China MediTech Limited announced today the pricing of the underwritten public offering previously announced by Chi-Med on October 24, 2017.

  October 26, 2017

   · 

  5 min read
• Business

  Ipsen Delivers Strong Sales Growth of 22.6% for the Third Quarter of 2017 and Confirms Full Year Guidance

  Ipsen, a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2017.

  October 26, 2017

   · 

  29 min read
• Policy

  FDA Accepts Genentech’s Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women With Advanced Ovarian Cancer

  Genentech announced today that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) for Avastin (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of women with advanced ovarian cancer.

  October 26, 2017

   · 

  10 min read
• Business

  Evotec and TESARO Enter Strategic Partnership to Discover Novel Immuno-Oncology Agents

  Evotec and TESARO today announced a three-year integrated drug discovery collaboration to discover and develop novel small molecule product candidates against an undisclosed immuno-oncology (IO) target.

  October 26, 2017

   · 

  4 min read
• Business

  Medivir AB - Interim Report, January - September 2017

  Positive topline results from phase IIa osteoarthritis study showed disease-modifying benefit and an acceptable safety and tolerability in this patient population.

  October 26, 2017

   · 

  7 min read
• Angle PLC: Total Voting Rights

  ANGLE plc. announces that, following the announcement of 12 October 2017, 7,481,570 New Ordinary Shares have been issued pursuant to the Further Subscription.

  October 26, 2017

   · 

  3 min read
• Business

  Epidarex Capital Appoints Three Leading Industry Executives to its Advisory Board

  Epidarex Capital, an early-stage, transatlantic life science venture fund, announces the appointment of Dr. William R Sellers, William Burns and Dr. Frank M Armstrong to its advisory board.

  October 26, 2017

   · 

  6 min read
• Policy

  Mylan Wins U.K. Court Ruling Related to Copaxone 40 mg/mL Patent

  Mylan today announced that the United Kingdom’s High Court of Justice has issued a decision in favor of Mylan and its European partner Synthon, finding all claims of Teva’s patent EP (UK) 2 949 335 (EP 335) relating to Copaxone 40 mg/mL invalid based on obviousness.

  October 26, 2017

   · 

  5 min read
• Business

  Achieve Announces Exclusive, Long-term Manufacturing Agreement with Sopharma for Clinical and Commercial Supply of Cytisine

  Achieve Life Science today announced it has entered into an exclusive supply agreement with Sopharma AD for the manufacture of cytisine API and finished tablets.

  October 26, 2017

   · 

  5 min read